The DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index.
The Use of Therapeutic Peptides to Target and to Kill Cancer Cells
Abstract
Peptide therapeutics is a promising field for emerging anti-cancer agents. Benefits include the ease and rapid synthesis of peptides and capacity for modifications. An existing and vast knowledge base of protein structure and function can be exploited for novel peptide design. Current research focuses on developing peptides that can (1) serve as tumor targeting moieties and (2) permeabilize membranes with cytotoxic consequences. A survey of recent findings reveals significant trends. Amphiphilic peptides with clusters of hydrophobic and cationic residues are features of anti-microbial peptides that confer the ability to eradicate microbes and show considerable anti-cancer toxicity. Peptides that assemble and form pores can disrupt cell or organelle membranes and cause apoptotic or necrotic death. Cell permeable and tumor-homing peptides can carry biologically active cargo to tumors or tumor vasculature. The challenge lies in developing the clinical application of therapeutic peptides. Improving delivery to tumors, minimizing non-specific toxic effects and discerning pharmacokinetic properties are high among the needs to produce a powerful therapeutic peptide for cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, this strategy has several drawbacks that usually arise due to their limited bioavailability and specificity [115,116].”
From The Role of RhoH in TCR Signalling and Its Involvement in Diseases (2021) · cites this paper as [115]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Integrins in cancer: biological implications and therapeutic opportunities
Desgrosellier, J. S., & Cheresh, D. A. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2748 · Cited by 3,855
Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells
Vaux, D. L., Cory, S., & Adams, J. M. (1988) · Nature · doi:10.1038/335440a0 · Cited by 3,219
Requirement of Vascular Integrin α v β 3 for Angiogenesis
Brooks, P. C., Clark, R. A. F., & Cheresh, D. A. (1994) · Science · doi:10.1126/science.7512751 · Cited by 3,020
Cellular uptake of the tat protein from human immunodeficiency virus
Frankel, A. D., & Pabo, C. O. (1988) · Cell · doi:10.1016/0092-8674(88)90263-2 · Cited by 2,782
In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse
Schwarze, S. R., Ho, A. L., Vocero-Akbani, A. M., & Dowdy, S. F. (1999) · Science · doi:10.1126/science.285.5433.1569 · Cited by 2,418
Zasloff, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.15.5449 · Cited by 2,305
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
Arap, W., Pasqualini, R., & Ruoslahti, E. (1998) · Science · doi:10.1126/science.279.5349.377 · Cited by 2,054
Green, M., & Loewenstein, P. M. (1988) · Cell · doi:10.1016/0092-8674(88)90262-0 · Cited by 1,553
Cited by
Biomedical applications of nisin
Shin, J. M., Gwak, J. W., Kamarajan, P., Fenno, J. C., Rickard, A. H., & Kapila, Y. L. (2016) · Journal of Applied Microbiology · doi:10.1111/jam.13033 · Cited by 607
Peptides as drug delivery vehicles across biological barriers
Ghosh, D., Peng, X., Leal, J., & Mohanty, R. P. (2018) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-017-0374-0 · Cited by 102
The Role of RhoH in TCR Signalling and Its Involvement in Diseases
Ahmad Mokhtar, A. M., Hashim, I. F., Mohd Zaini Makhtar, M., Salikin, N. H., & Amin-Nordin, S. (2021) · Cells · doi:10.3390/cells10040950 · Cited by 25
Enhancing microalgal proteins for nutraceutical and functional food applications
Kaur, M., Bhatia, S., Bagchi, D., Tak, Y., Kaur, G., Kaur, C., Kaur, A., & Sharma, N. (2025) · Future Foods · doi:10.1016/j.fufo.2025.100564 · Cited by 19
Metadata
- Authors
- J. Boohaker, R., W. Lee, M., Vishnubhotla, P., M. Perez, J. L., & R. Khaled, A.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-06-01
- Volume
- 19
- Issue
- 22
- Pages
- 3794-3804
- ISSN
- 0929-8673
- PMC
- PMC4537071
- Cited by
- 302
- References
- 129
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
